{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T14:06:45Z","timestamp":1773238005138,"version":"3.50.1"},"reference-count":39,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2012,6,14]],"date-time":"2012-06-14T00:00:00Z","timestamp":1339632000000},"content-version":"vor","delay-in-days":44,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Exper Ophthalmology"],"published-print":{"date-parts":[[2012,5]]},"abstract":"<jats:title>A<jats:sc>bstract<\/jats:sc><\/jats:title><jats:p><jats:bold>Background:\u2002<\/jats:bold> The present study compared the effects of adjuvant bevacizumab and 5\u2010fluorouracil on the efficacy and safety of trabeculectomy.<\/jats:p><jats:p><jats:bold>Design:\u2002<\/jats:bold> A nonrandomized, prospective, interventional case study.<\/jats:p><jats:p><jats:bold>Participants:\u2002<\/jats:bold> A total of 62 patients in two groups undergoing primary trabeculectomy.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> In Group 1 (21 primary open\u2010angle glaucoma, nine pseudoexfoliative glaucoma), trabeculectomy was performed with an adjuvant 5% solution of 5\u2010fluorouracil administered for 4\u2003min, intraoperatively. In Group 2 (21 primary open\u2010angle glaucoma, 11 pseudoexfoliative glaucoma), trabeculectomy was enhanced with 1.25\u2003mg of bevacizumab applied subconjunctivally immediately before and after surgery and again 1 and 7\u2003days after surgery.<\/jats:p><jats:p><jats:bold>Main Outcome Measures:\u2002<\/jats:bold> Intraocular pressure, best corrected visual acuity, visual field index, bleb morphology, cornel endothelial cell count.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> Mean intraocular pressure was 28.0\u2003\u00b1\u20038.0\u2003mmHg before 5\u2010fluorouracil\u2010augmented trabeculectomy and 27.8\u2003\u00b1\u20039.5\u2003mmHg before bevacizumab\u2010augmented trabeculectomy. After 12\u2003months, mean intraocular pressure was 13.6\u2003\u00b1\u20034.4\u2003mmHg in the 5\u2010fluorouracil group and 14.7\u2003\u00b1\u20034.7\u2003mmHg in the bevacizumab group. A 30% reduction of initial intraocular pressure was attained in 86.7% of patients in the 5\u2010fluorouracil group and 78.1% of patients in the bevacizumab group at the end of follow up. No significant differences were noted between the two studied groups with respect to corneal endothelial density, visual field indices and postoperative complications.<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold> The 12\u2010month intraocular pressure results showed no significant differences between the two groups of patients after bevacizumab or 5\u2010fluorouracil to augment trabeculectomy. However, to obtain successful intraocular pressure control more patients in bevacizumab group needed medical therapy.<\/jats:p>","DOI":"10.1111\/j.1442-9071.2011.02608.x","type":"journal-article","created":{"date-parts":[[2011,6,13]],"date-time":"2011-06-13T19:06:06Z","timestamp":1307991966000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Comparison of the use of 5\u2010fluorouracil and bevacizumab in primary trabeculectomy: results at 1\u2003year"],"prefix":"10.1111","volume":"40","author":[{"given":"Justyna","family":"Jurkowska\u2010Dudzi\u0144ska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Kosior\u2010Jarecka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"\u017barnowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,6,14]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9394(68)91288-9"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1983.01040010795021"},{"key":"e_1_2_5_4_2","volume-title":"Glaucoma: Diagnosis and Management of Chronic Open Angle Glaucoma and Ocular Hypertension","author":"National Collaborating Centre for Acute Care","year":"2009"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6257(03)00038-9"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.03.050"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.10.5638"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/380435a0"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)49853-0"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2005.11.019"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.05.064"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2007.11.003"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e318159019f"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00061198-200412000-00005"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1159\/000099248"},{"key":"e_1_2_5_16_2","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3928\/1542-8877-20060301-11","article-title":"Intravitreal bevacizumab in a patient with neovascular glaucoma","volume":"37","author":"Kahook MY","year":"2006","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"e_1_2_5_17_2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3928\/1542-8877-20060301-12","article-title":"Needle bleb revision of encapsulated filtering bleb with bevacizumab","volume":"37","author":"Kahook MY","year":"2006","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"e_1_2_5_18_2","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ajo.2006.02.045","article-title":"Intracameral bevacizumab for iris rubeosis","volume":"142","author":"Grisanti S","year":"2006","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"e_1_2_5_19_2","first-page":"S162","article-title":"Intravitreal bevacizumab for Ahmed glaucoma valve implantation in neovascular glaucoma: a case report","volume":"91","author":"Sothornwit N","year":"2008","journal-title":"J Med Assoc Thai"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2008.06.009"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.85.9.1028"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2008.09.049"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)72386-4"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(02)01627-6"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00061198-200012000-00004"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.125.8.1044"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2008.11.016"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-9071.2008.01683.x"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0b013e328325a54b"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2005.21.223"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1745-7254.2008.00833.x"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1995.01100050044028"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-005-1170-5"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuro.2008.06.006"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e3180de1d0a"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0420.2007.01049.x"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1006\/exer.1994.1037"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.02483"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.08-2441"},{"key":"e_1_2_5_40_2","first-page":"e605","article-title":"Topical bevacizumab is efficacious in the early bleb failure after trabeculectomy","volume":"87","author":"Zarnowski T","year":"2009","journal-title":"Acta Ophthalmol"}],"container-title":["Clinical &amp; Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1442-9071.2011.02608.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1442-9071.2011.02608.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T11:09:10Z","timestamp":1698750550000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1442-9071.2011.02608.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["10.1111\/j.1442-9071.2011.02608.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1442-9071.2011.02608.x","archive":["Portico"],"relation":{},"ISSN":["1442-6404","1442-9071"],"issn-type":[{"value":"1442-6404","type":"print"},{"value":"1442-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5]]},"assertion":[{"value":"2012-06-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}